Oruka Therapeutics stock price target raised to $56 at BTIG on promising drug data
PositiveFinancial Markets

Oruka Therapeutics has received a boost as BTIG raised its stock price target to $56, following promising data from its latest drug trials. This positive development not only reflects confidence in the company's potential but also highlights the growing interest in innovative therapies. Investors and stakeholders are keenly watching how this will impact the company's market position and future growth.
— Curated by the World Pulse Now AI Editorial System